Pharmaceuticals - BioReview (Page 6)

Biotechnology

AbbVie's $1.2 Billion Zelgen Deal Signals Major Push Into T-Cell Engager Market

AbbVie kicked off 2026 with a strategic bang, announcing a potentially $1.2 billion licensing deal with China's Suzhou Zelgen Biopharmaceuticals for exclusive rights to develop and commercialize alveltamig (ZG-006) outside of Greater China. The New Year's Eve agreement represents one of the largest T-cell engager

Pharmaceuticals

Year-End FDA Rejections Deliver Harsh Reality Check to Sanofi and Corcept

The final days of 2025 delivered unwelcome surprises to two pharmaceutical companies as the FDA issued complete response letters rejecting drug applications from both Sanofi and Corcept Therapeutics. These unexpected regulatory setbacks underscore the unpredictable nature of drug approval processes and highlight how even promising therapies with strong clinical data

Biotechnology

FibroBiologics Pioneers Novel Fibroblast Spheroid Therapy for Psoriasis with FDA Filing

FibroBiologics files IND application for CYPS317, marking the first fibroblast spheroid-based therapy to enter clinical development for psoriasis, with compelling preclinical data showing superior durability compared to existing biologic treatments.